Alpha Holdings expands oncosec pipeline to lung cancer ... Melanoma Clinical Phase 2 Cruising
Oncosec, the largest shareholder of Alpha Holdings, will enter the lung cancer treatment market with its immunotherapeutic drug Interleukin-12 (IL-12).
Clinical trial 2b for melanoma cancer is also underway and it is expected to be available early in 2020.
The company plans to expand its pipeline (new drug candidates) to the market for large-scale lung cancer by launching a new product on March 3
To this end, it is developing a dedicated electric perforation device (ImmunoPulse platform).
In the case of lung cancer, the preclinical phase and clinical phase 1 are already completed in different indications,
"The details will be decided by consultation with the US Food and Drug Administration (FDA) and will be officially announced at the time of confirmation.
Oncocek injects immunomodulators directly around the cancer cells. Since then, the patented electric punching technology,
Then, it is injected into cancer cells and expressed locally. It is the way that the immune antibody empowers itself to fight cancer cells.
The technology of Oncocek is attracting attention because Merck (product name Kit Luda), BMS (product name Honey · obdibo) which is the first immune barrier inhibitor big medicine of cancer treatment attracts attention
This is because it is a second-line immunotherapy for rare-disease patients who have not been treated. In fact, most of the major clinical trials use interleukin-12 with Kitroda
And the like.
Among the currently available pipelines, melanoma is the most rapid indication for clinical progression. The Keynote-695 for the melanoma 3-4 severe patients
In phase 2b, the company will ask the FDA to appoint a fast track dedicated to rare drugs next year. By the end of next year,
We will go on sale early. Alfa USA, a subsidiary of the US, has also been established to strengthen marketing and strengthen the BT (biotech) business.
Keynote-890, a triple-negative breast cancer pipeline, began recruiting patients on the first day of the month for Phase 2 clinical trials. The results are expected to be drawn up at the end of next year
Initial data will be released in the first half of next year. OMS-131, a two-head cancer pipeline, is expected to enter Phase 2 clinical trials by delivering patients early next year.
Alpha Holdings also accepted that it has a low stake in Oncocec. Alpha Holdings, the largest shareholder in Oncocek, owns 15.65%
All. As major shareholders are willing to exercise the call option granted to convertible bonds (CB), the shareholding rate should be raised to 20%
It is a concept of strengthening.
AI
